Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax’s CpG 1018™ Adjuvant
Excerpt from the Press Release:
EMERYVILLE, Calif., April 21, 2021 /PRNewswire/ — DYNAVAX TECHNOLOGIES CORPORATION (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced Valneva SE has initiated a pivotal Phase 3 clinical trial for its inactivated, COVID-19 vaccine candidate, VLA2001, using Dynavax’s CpG 1018 adjuvant. The Phase 3 trial “Cov-Compare”, (VLA2001-301), will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial.
The initiation of the Cov-Compare trial follows positive initial results from Valneva’s Phase 1/2 clinical trial, which demonstrated that the safety profile and immunogenicity were supportive of further development.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?